SCHEMBL3386992

SCHEMBL3386992

CCN1CCC(OS(=O)(=O)c2ccc(C)cc2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.58
CYP1A2 P05177 1/20 0.52
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
DRD4 P21917 1/20 0.42
DRD5 P21918 1/20 0.42
DRD3 P35462 1/20 0.42
ALDH1A1 P00352 5/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
LMNA P02545 3/20 0.38
FPR2 P25090 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14891143 1.00 CYP2D6 (0.58) CYP2D6CYP1A2DRD2DRD1DRD4
SCHEMBL3562444 0.83 HTR6 (0.53) CYP2D6CYP1A2ALDH1A1LMNAPOLB
SCHEMBL952495 0.83 HTR6 (0.53) CYP2D6CYP1A2ALDH1A1LMNAPOLB
SCHEMBL952496 0.83 HTR6 (0.53) CYP2D6CYP1A2ALDH1A1LMNAPOLB
SCHEMBL3388527 0.81 CYP2D6 (0.74) CYP2D6CYP1A2DRD2DRD1DRD4
SCHEMBL420300 0.81 CYP2D6 (0.74) CYP2D6CYP1A2DRD2DRD1DRD4
SCHEMBL31755601 0.80 CYP2D6 (0.57) CYP2D6CYP1A2DRD2DRD1DRD4
SCHEMBL21292323 0.80 CYP2D6 (0.64) CYP2D6CYP1A2DRD2DRD1DRD4
SCHEMBL3235228 0.79 CYP2D6 (0.59) CYP2D6CYP1A2ALDH1A1KMT2AMEN1
SCHEMBL3235232 0.79 CYP2D6 (0.59) CYP2D6CYP1A2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109854-A1 Novel Methods for Preparation of (+)-1-ethyl-4-[2-(4-morpholinyl)ethyl)-3,3-diphenyl-2-pyrrolidinone and Salts Thereof GALLEON PHARMACEUTICALS, INC. 2013-05-02 US disclosed
EP-2029534-B1 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-22 EP disclosed
EP-2029534-A2 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-03-04 EP disclosed
US-7432255-B2 1H-indol-5-yl-piperazin-1-yl-methanone derivatives HOFFMANN-LA ROCHE INC. (US) 2008-10-07 US disclosed
WO-2007131907-A2 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-11-22 WO disclosed
US-20070270423-A1 IH-indol-5-YL-piperazin-1-YL-methanone derivatives HOFFMANN-LA ROCHE INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109854-A1 Novel Methods for Preparation of (+)-1-ethyl-4-[2-(4-morpholinyl)ethyl)-3,3-diphenyl-2-pyrrolidinone and Salts Thereof TNNC1, DNPEP, TNNT2 CYP2D6 35/4885CYP1A2 389/4885DRD2 3137/4885
US-20070270423-A1 IH-indol-5-YL-piperazin-1-YL-methanone derivatives HRH4, HRH2, HRH3 CYP2D6 387/4885CYP1A2 351/4885DRD2 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.